S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

$2.19
-0.02 (-0.90%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$2.18
$2.33
50-Day Range
$2.19
$3.70
52-Week Range
$1.40
$7.75
Volume
64,000 shs
Average Volume
263,871 shs
Market Capitalization
$57.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Immix Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
539.3% Upside
$14.00 Price Target
Short Interest
Healthy
2.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Immix Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.91) to ($0.94) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

Medical Sector

639th out of 908 stocks

Pharmaceutical Preparations Industry

287th out of 424 stocks

IMMX stock logo

About Immix Biopharma Stock (NASDAQ:IMMX)

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

IMMX Stock Price History

IMMX Stock News Headlines

Immix Biopharma, Inc. (IMMX)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
IMMX Apr 2024 7.500 call
Immix Biopharma 12 Month Review Progress Update
Immix Biopharma 12 Month Review Progress Update
Immix Biopharma 12 Month Review Progress Update
IMMX Aug 2024 2.500 call
Immix Biopharma Signs Definitive $15M Titan Partnership Deal
See More Headlines
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/22/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMMX
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+539.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.81 per share

Miscellaneous

Free Float
11,641,000
Market Cap
$57.82 million
Optionable
Optionable
Beta
0.05
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Ilya Rachman M.B.A. (Age 51)
    M.D., MBA, Ph.D., Co-Founder, CEO & Chairman
    Comp: $637.5k
  • Mr. Gabriel Morris B.A. (Age 37)
    CFO & Director
    Comp: $637.5k
  • Mr. Sean Senn J.D.
    M.B.A., M.Sc., MBA, MSc, Co-Founder
  • Dr. Vladimir P. Torchilin D.Sc. (Age 77)
    MSE, Ph.D., Scientific Co-Founder
  • Mr. Ben H. Lyon J.D.
    Executive VP & General Counsel
  • Dr. Graham Ross FFPM (Age 64)
    M.D., Chief Medical Officer & Head of Clinical Development
  • Mr. Nandan Oza B.S. (Age 62)
    Head of Chemistry, Manufacturing & Control
  • Dr. David Marks
    Chief Medical Officer of Cell Therapy
  • Mr. Gerhard Bauer
    Head of Cell Thearpy Manufacturing

IMMX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immix Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMMX shares.
View IMMX analyst ratings
or view top-rated stocks.

What is Immix Biopharma's stock price target for 2024?

1 brokers have issued 1-year price objectives for Immix Biopharma's shares. Their IMMX share price targets range from $14.00 to $14.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 539.3% from the stock's current price.
View analysts price targets for IMMX
or view top-rated stocks among Wall Street analysts.

How have IMMX shares performed in 2024?

Immix Biopharma's stock was trading at $6.92 at the beginning of 2024. Since then, IMMX stock has decreased by 68.4% and is now trading at $2.19.
View the best growth stocks for 2024 here
.

When is Immix Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IMMX earnings forecast
.

When did Immix Biopharma IPO?

Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMMX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners